Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Investors scramble to buy Microsaic on biotech research partnership news
Thursday 21 Dec 2017 Author: Steven Frazer

Mass spectrometry instruments minnow Microsaic Systems (MSYS:AIM) has finally burst to life, in terms of its share price.

Shares in the £5m micro-cap business soared 152% in a single day (the stock was up 363% at one point) after unveiling an extension to a biotechnology research partnership that may eventually lead to a scalable market.

The agreement is focused on medical bioprocessing and diagnostics. Bioprocessing uses living cells to test applications. Mass spectrometry is a form of materials science that measures the mass-to-charge relationship of substances, used in many industrial applications.

Microsaic designs mass spectrometry machines small enough to be desktop mounted. After years of seeding various industries (food testing was at one time a great hope) it still lacks any reasonable scale and runs at a loss.

‹ Previous2017-12-21Next ›